We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > HemoShear

News List

HemoShear Identifies Novel Drug Target to Treat NASH in Partnership with Takeda americanpharmaceuticalreview
December 31, 2020
HemoShear Therapeutics has achieved a research milestone in its discovery and development collaboration with Takeda Pharmaceutical to advance its first nonalcoholic steatohepatitis (NASH) target into Takeda's discovery portfolio.
SmartZyme spins off protein tech company for a metabolic disease partnership with Hemoshear fiercebiotech
January 02, 2019
SmartZyme BioPharma is spinning off its protein-based therapeutic platform into a new company—dubbed Carnot BioSciences—as part of a collaboration with Hemoshear Therapeutics aimed at rare metabolic diseases.....
Takeda and HemoShear partner to discover new treatments for liver diseases pharmaceufical-technology
October 20, 2017
NASH is a serious, chronic liver disease characterised by inflammation and excessive fat accumulation in the liver, which may lead to fibrosis, cirrhosis, liver cancer and eventually liver failure.